Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Ado

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook art

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may pr

Leerink Partners analyst Thomas Smith initiates coverage on Altimmune (NASDAQ:ALT) with a Outperf

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?

Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc

Altimmune NASDAQ: ALT management used an appearance at the Goldman Sachs Global Healthcare Conferenc

Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 da

Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that

ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set

Altimmune NASDAQ: ALT executives said the company is preparing to begin enrolling patients in the se

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or d

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data

“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and

GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-s

Concurrent improvement across key non-invasive tests underscores convergence of  pemvidutide effects

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA

ALT advances pemvidutide in MASH, AUD and ALD, with phase III plans and promising liver disease data

ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash run

Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as t

  On Friday, 1043 companies hit new 52-week lows.

  On Friday, 431 companies hit new 52-week lows.

Stocks Which Set New 52-Week Low Yesterday, October 11th

Are Hedge Fund ETFs Worth The Trouble?